Cencora Stock (COR)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Cencora, formerly AmerisourceBergen, is a pharmaceutical wholesaler from Pennsylvania. The company supplies pharmacies, hospitals and doctors’ offices with medicines, offers services to drug manufacturers and is also active in animal health, mainly in the US and Europe. As of Oct 13, 2026

Fact sheet (from the annual report) Wholesale of drugs and drugstore products · Conshohocken, USA

Cencora distributes pharmaceuticals and provides services to healthcare providers and to pharmaceutical and biotech manufacturers, in both human and animal health. The US segment supplies branded drugs, specialty drugs, generics, over-the-counter products and home care supplies to hospitals, pharmacy chains, independent pharmacies and mail-order pharmacies. This includes specialty drugs for physician specialists, especially in oncology and retina care, as well as an animal health business for pets and livestock. The international segment supplies pharmacies, doctors and hospitals mainly in Europe and offers pharmaceutical companies specialty logistics and consulting, for example on regulatory approval and drug safety. In fiscal year 2025 a significant share of revenue came from Walgreens and Boots as well as from Evernorth Health Services.

Automatically summarized from SEC annual report (10-K, filed Nov 25, 2025) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.6%
  • 7 days −5.6%
  • 30 days −0.4%
  • 1 year −6.4%
Day range (last trading day)
−0.4%Price at 12% of the range+2.8%
52-week range
−27.8%Price at 71% of the range+11.3%
Distance from the all-time high
−10.2%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Cencora · Sector Health Care · amounts in USD

Source: SEC filings, As of Nov 25, 2025.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 7.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.8%
dividend per share, average per year
Coverage by free cash flow
7.5x
covered from 1.0x

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 6
criteria with data met
Revenue per year (5 y)
+11.1%
EPS per year (3 y)
−0.3%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
2 of 7
criteria with data met
Net margin
0.5%
Cash flow ÷ profit
2.47x
backed from 1.0 · 3 years: 2.34x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Sep 30, 2025

Quality 2 of 7 met · 1 without data

  • not met: Gross margin above 40% 3.6%
  • not met: Operating margin above 15% 0.8%
  • not met: Net margin above 10% 0.5%
  • no data: Return on equity above 15% equity below 5% of total assets – return on equity not meaningful
  • not met: Free cash flow margin above 10% 1.0%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% 2.0%
Gross margin

3.6% Fiscal year 2025

Rank 1 of 100: higher than 1% of 370 peers (All). weak.

Rank 1 of 100: higher than 1% of 49 peers (Sector). weak.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

0.8% Fiscal year 2025

Rank 17 of 100: higher than 17% of 470 peers (All). weak.

Rank 14 of 100: higher than 14% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

0.5% Fiscal year 2025

Rank 14 of 100: higher than 14% of 584 peers (All). weak.

Rank 13 of 100: higher than 13% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on assets

2.0% Fiscal year 2025 (total assets at year end)

Rank 26 of 100: higher than 26% of 594 peers (All). weak.

Rank 15 of 100: higher than 15% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

2.0% Fiscal year 2025

Rank 6 of 100: higher than 6% of 595 peers (All). weak.

Rank 13 of 100: higher than 13% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

1.0% Fiscal year 2025

Rank 18 of 100: higher than 18% of 465 peers (All). weak.

Rank 11 of 100: higher than 11% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

3.2B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 6 met · 1 without data

  • met: Over 3 years, revenue grew by more than 5% per year +10.4%
  • met: Over 5 years, revenue grew by more than 5% per year +11.1%
  • met: Over 10 years, revenue grew by more than 5% per year +9.0%
  • not met: Over 3 years, EPS grew by more than 5% per year −0.3%
  • no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first year, or figures missing)
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +9.3%
Revenue growth 3 years

+10.4% per year

Rank 69 of 100: higher than 69% of 578 peers (All). strong.

Rank 75 of 100: higher than 75% of 62 peers (Sector). strong.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+11.1% per year

Rank 62 of 100: higher than 62% of 549 peers (All). medium.

Rank 69 of 100: higher than 69% of 60 peers (Sector). strong.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+9.0% per year

Rank 65 of 100: higher than 65% of 412 peers (All). medium.

Rank 45 of 100: higher than 45% of 50 peers (Sector). medium.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−0.3% per year

Rank 31 of 100: higher than 31% of 437 peers (All). weak.

Rank 32 of 100: higher than 32% of 54 peers (Sector). weak.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 2.20 USD
  • met: Payout ratio at most 60% of earnings 28%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +5.8%
  • met: Free cash flow per share covers the dividend 7.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 14% of free cash flow
Payout ratio

28% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+5.8% per year

Rank 38 of 100: higher than 38% of 321 peers (All). medium.

Rank 40 of 100: higher than 40% of 31 peers (Sector). medium.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

7.5x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 4 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • not met: Long-term debt no higher than equity 5.08
  • not met: Current assets cover current liabilities 0.90
  • met: Positive equity 1.5B USD
  • met: In 5 years, share count up by at most 5% −4.7%
  • met: Free cash flow positive in the last fiscal year 3.2B USD
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 69 of 100: higher than 69% of 310 peers (All). strong.

Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

5.08 at fiscal year end

Rank 4 of 100: lower than 4% of 486 peers (All). weak.

Rank 3 of 100: lower than 3% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.90 at fiscal year end

Rank 20 of 100: higher than 20% of 513 peers (All). weak.

Rank 12 of 100: higher than 12% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−4.7% in 5 years

Rank 57 of 100: lower than 57% of 507 peers (All). medium.

Rank 52 of 100: lower than 52% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+11.1% per year), at least as fast as the sector median.
  • Light yellow: Net margin 0.5%, below the sector median (13.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light yellow: Profit in 9 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Oct 1, 2015 – Sep 30, 2016): Revenue 146.8B USD · Net income 1.4B USD · Net margin 1.0%
  2. Fiscal year 2017 (Oct 1, 2016 – Sep 30, 2017): Revenue 153.1B USD · Net income 364.5M USD · Net margin 0.2%
  3. Fiscal year 2018 (Oct 1, 2017 – Sep 30, 2018): Revenue 167.9B USD · Net income 1.7B USD · Net margin 1.0%
  4. Fiscal year 2019 (Oct 1, 2018 – Sep 30, 2019): Revenue 179.6B USD · Net income 855.4M USD · Net margin 0.5%
  5. Fiscal year 2020 (Oct 1, 2019 – Sep 30, 2020): Revenue 189.9B USD · Net income −3.4B USD · Net margin −1.8%
  6. Fiscal year 2021 (Oct 1, 2020 – Sep 30, 2021): Revenue 214.0B USD · Net income 1.5B USD · Net margin 0.7%
  7. Fiscal year 2022 (Oct 1, 2021 – Sep 30, 2022): Revenue 238.6B USD · Net income 1.7B USD · Net margin 0.7%
  8. Fiscal year 2023 (Oct 1, 2022 – Sep 30, 2023): Revenue 262.2B USD · Net income 1.7B USD · Net margin 0.7%
  9. Fiscal year 2024 (Oct 1, 2023 – Sep 30, 2024): Revenue 294.0B USD · Net income 1.5B USD · Net margin 0.5%
  10. Fiscal year 2025 (Oct 1, 2024 – Sep 30, 2025): Revenue 321.3B USD · Net income 1.6B USD · Net margin 0.5%

Fiscal year 2025 (Oct 1, 2024 – Sep 30, 2025): Revenue 321.3B USD · Net income 1.6B USD · Net margin 0.5%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Jun 2026 +5.1% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.

Revenue 12 months vs. prior 12
+5.1%
12 months: 332.8B USD · Fiscal year 2025: +9.3%
Net margin 12 months
0.8%
Fiscal year 2025: 0.5%
Free cash flow margin 12 months
1.2%
Fiscal year 2025: 1.0%
More depth

Calculation of the 12 months to Jun 30, 2026

  • Revenue: fiscal year to Sep 30, 2025 321.3B USD + year to date to Jun 30, 2026 249.0B USD − same period a year earlier to Jun 30, 2025 237.6B USD = 332.8B USD
  • Net income: fiscal year to Sep 30, 2025 1.6B USD + year to date to Jun 30, 2026 3.0B USD − same period a year earlier to Jun 30, 2025 1.9B USD = 2.6B USD
  • Operating cash flow: fiscal year to Sep 30, 2025 3.9B USD + year to date to Jun 30, 2026 1.7B USD − same period a year earlier to Jun 30, 2025 741.7M USD = 4.8B USD
  • Capital expenditure: fiscal year to Sep 30, 2025 668.0M USD + year to date to Jun 30, 2026 511.0M USD − same period a year earlier to Jun 30, 2025 418.2M USD = 760.8M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Apr–Jun 2684.8B+5.1%763.5M0.9%
Jan–Mar 2678.4B+3.8%1.6B2.1%
Oct–Dec 2585.9B+5.5%559.6M0.7%
Jul–Sep 25*83.7B+5.9%−339.7M−0.4%
Apr–Jun 2580.7B+8.7%687.4M0.9%
Jan–Mar 2575.5B+10.3%717.9M1.0%
Oct–Dec 2481.5B+12.8%488.6M0.6%
Jul–Sep 24*79.1B+14.7%3.4M0.0%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Jun 30, 2026, filed on Aug 5, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
2.47x
backed from 1.0 · 3 years: 2.34x
Interest coverage
9.0x
well covered from 5 · net interest expense · 3 years: 10.5x
Tax rate
30.6%
for information only · 3 years: 25.0%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 3.9B USD ÷ group profit incl. minority interests 1.6B USD = 2.47x
  • Operating income 2.6B USD ÷ net interest expense 291.5M USD = 9.0x
  • Taxes 690.5M USD ÷ profit before tax 2.3B USD = 30.6%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20252.47x9.0x30.6%
20242.29x13.9x24.2%
20232.26x10.2x19.8%
20221.62x11.2x23.7%
20211.73x13.5x30.5%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years one loss year and no year with lower revenue.

Loss years
1 of 10
net income below zero
Years with lower revenue
0 of 10
revenue below the prior year
Net margin range
2.8 percentage points
from −1.8% to 1.0%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+9.3%0.5%
2024+12.1%0.5%
2023+9.9%0.7%
2022+11.5%0.7%
2021+12.7%0.7%
2020+5.7%−1.8%
2019+6.9%0.5%
2018+9.7%1.0%
2017+4.3%0.2%
2016+8.0%1.0%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 3.6 USD gross profit, 0.8 USD operating income and 0.5 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue321.3B USD100.0%
Gross profit11.5B USD3.6%
Cost of revenue309.9B USD96.4%
Operating income2.6B USD0.8%
Operating expenses8.8B USD2.8%
Net income1.6B USD0.5%
Taxes690.5M USD0.2%
Interest & other383.9M USD0.1%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from −2.7% to 0.8%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 2.9% · Operating margin 1.0% · Net margin 1.0%
  2. Fiscal year 2017: Gross margin 3.0% · Operating margin 0.7% · Net margin 0.2%
  3. Fiscal year 2018: Gross margin 2.7% · Operating margin 0.9% · Net margin 1.0%
  4. Fiscal year 2019: Gross margin 2.9% · Operating margin 0.6% · Net margin 0.5%
  5. Fiscal year 2020: Gross margin 2.7% · Operating margin −2.7% · Net margin −1.8%
  6. Fiscal year 2021: Gross margin 3.2% · Operating margin 1.1% · Net margin 0.7%
  7. Fiscal year 2022: Gross margin 3.5% · Operating margin 1.0% · Net margin 0.7%
  8. Fiscal year 2023: Gross margin 3.4% · Operating margin 0.9% · Net margin 0.7%
  9. Fiscal year 2024: Gross margin 3.4% · Operating margin 0.7% · Net margin 0.5%
  10. Fiscal year 2025: Gross margin 3.6% · Operating margin 0.8% · Net margin 0.5%

Returns

Return on equity fell in 3 years from 67.1% to 29.7%.

Return on equityReturn on assets Return on equity hidden where equity is below 5% of total assets.
  1. Fiscal year 2016: Return on equity 67.1% · Return on assets 4.2%
  2. Fiscal year 2017: Return on equity 17.7% · Return on assets 1.0%
  3. Fiscal year 2018: Return on equity 56.5% · Return on assets 4.4%
  4. Fiscal year 2019: Return on equity 29.7% · Return on assets 2.2%
  5. Fiscal year 2020: Return on equity not available · Return on assets −7.7%
  6. Fiscal year 2021: Return on equity not available · Return on assets 2.7%
  7. Fiscal year 2022: Return on equity not available · Return on assets 3.0%
  8. Fiscal year 2023: Return on equity not available · Return on assets 2.8%
  9. Fiscal year 2024: Return on equity not available · Return on assets 2.2%
  10. Fiscal year 2025: Return on equity not available · Return on assets 2.0%

Equity and long-term debt

The equity ratio rose in 5 years from −2.3% to 2.0%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 2.1B USD · Long-term debt 4.2B USD
  2. Fiscal year 2017: Equity 2.1B USD · Long-term debt 3.4B USD
  3. Fiscal year 2018: Equity 2.9B USD · Long-term debt not available
  4. Fiscal year 2019: Equity 2.9B USD · Long-term debt 4.2B USD
  5. Fiscal year 2020: Equity −1.0B USD · Long-term debt 4.1B USD
  6. Fiscal year 2021: Equity 223.4M USD · Long-term debt 6.7B USD
  7. Fiscal year 2022: Equity −211.6M USD · Long-term debt 5.7B USD
  8. Fiscal year 2023: Equity 522.0M USD · Long-term debt 4.8B USD
  9. Fiscal year 2024: Equity 645.9M USD · Long-term debt 4.4B USD
  10. Fiscal year 2025: Equity 1.5B USD · Long-term debt 7.7B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 0.98 to 0.90.

Current ratio
  1. Fiscal year 2016: Current ratio 0.90
  2. Fiscal year 2017: Current ratio 0.91
  3. Fiscal year 2018: Current ratio 0.93
  4. Fiscal year 2019: Current ratio 0.95
  5. Fiscal year 2020: Current ratio 0.98
  6. Fiscal year 2021: Current ratio 0.94
  7. Fiscal year 2022: Current ratio 0.91
  8. Fiscal year 2023: Current ratio 0.88
  9. Fiscal year 2024: Current ratio 0.88
  10. Fiscal year 2025: Current ratio 0.90

Cash flow

Free cash flow rose in 5 years from 1.8B USD to 3.2B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 3.2B USD · Capital expenditure 464.6M USD · Free cash flow 2.7B USD
  2. Fiscal year 2017: Operating cash flow 1.5B USD · Capital expenditure 466.4M USD · Free cash flow 1.0B USD
  3. Fiscal year 2018: Operating cash flow 1.4B USD · Capital expenditure 336.4M USD · Free cash flow 1.1B USD
  4. Fiscal year 2019: Operating cash flow 2.3B USD · Capital expenditure 310.2M USD · Free cash flow 2.0B USD
  5. Fiscal year 2020: Operating cash flow 2.2B USD · Capital expenditure 369.7M USD · Free cash flow 1.8B USD
  6. Fiscal year 2021: Operating cash flow 2.7B USD · Capital expenditure 438.2M USD · Free cash flow 2.2B USD
  7. Fiscal year 2022: Operating cash flow 2.7B USD · Capital expenditure 496.3M USD · Free cash flow 2.2B USD
  8. Fiscal year 2023: Operating cash flow 3.9B USD · Capital expenditure 458.4M USD · Free cash flow 3.5B USD
  9. Fiscal year 2024: Operating cash flow 3.5B USD · Capital expenditure 487.2M USD · Free cash flow 3.0B USD
  10. Fiscal year 2025: Operating cash flow 3.9B USD · Capital expenditure 668.0M USD · Free cash flow 3.2B USD

Share count

The share count fell in 5 years by 4.7% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 226.0M
  2. Fiscal year 2017: Diluted share count 221.6M
  3. Fiscal year 2018: Diluted share count 220.3M
  4. Fiscal year 2019: Diluted share count 211.8M
  5. Fiscal year 2020: Diluted share count 204.8M
  6. Fiscal year 2021: Diluted share count 208.5M
  7. Fiscal year 2022: Diluted share count 211.2M
  8. Fiscal year 2023: Diluted share count 204.6M
  9. Fiscal year 2024: Diluted share count 200.3M
  10. Fiscal year 2025: Diluted share count 195.2M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 189.9B USD to 321.3B USD.

COR in USD
  1. Fiscal year 2016: COR 146.8B USD
  2. Fiscal year 2017: COR 153.1B USD
  3. Fiscal year 2018: COR 167.9B USD
  4. Fiscal year 2019: COR 179.6B USD
  5. Fiscal year 2020: COR 189.9B USD
  6. Fiscal year 2021: COR 214.0B USD
  7. Fiscal year 2022: COR 238.6B USD
  8. Fiscal year 2023: COR 262.2B USD
  9. Fiscal year 2024: COR 294.0B USD
  10. Fiscal year 2025: COR 321.3B USD

Net margin

The net margin rose in 5 years from −1.8% to 0.5%.

COR Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: COR 1.0%
  2. Fiscal year 2017: COR 0.2%
  3. Fiscal year 2018: COR 1.0%
  4. Fiscal year 2019: COR 0.5%
  5. Fiscal year 2020: COR −1.8%
  6. Fiscal year 2021: COR 0.7%
  7. Fiscal year 2022: COR 0.7%
  8. Fiscal year 2023: COR 0.7%
  9. Fiscal year 2024: COR 0.5%
  10. Fiscal year 2025: COR 0.5% · Sector today 13.2%

Free cash flow margin

The free cash flow margin stayed roughly the same in 5 years (1.0%).

COR Sector today 14.7%
  1. Fiscal year 2016: COR 1.8%
  2. Fiscal year 2017: COR 0.7%
  3. Fiscal year 2018: COR 0.6%
  4. Fiscal year 2019: COR 1.1%
  5. Fiscal year 2020: COR 1.0%
  6. Fiscal year 2021: COR 1.0%
  7. Fiscal year 2022: COR 0.9%
  8. Fiscal year 2023: COR 1.3%
  9. Fiscal year 2024: COR 1.0%
  10. Fiscal year 2025: COR 1.0% · Sector today 14.7%

Source: SEC filings, fiscal years up to Sep 30, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 7.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.8%
dividend per share, average per year
Coverage by free cash flow
7.5x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 1.66 USD → fiscal year 2025 2.20 USD = +5.8% per year
  • Free cash flow per share 16.43 USD ÷ dividend per share 2.20 USD = 7.5x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.20 USD · Fiscal year 2025
Dividend growth per year
3 y +6.1%5 y +5.8%10 y +6.6%
Payout ratio
of earnings 28% of free cash flow 14%
To shareholders (5 years)
5.7B USD 65% through repurchases
Share count over 5 years
−4.7% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 1.66 USD to 2.20 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.36 USD
  2. Fiscal year 2017: Dividend per share 1.46 USD
  3. Fiscal year 2018: Dividend per share 1.52 USD
  4. Fiscal year 2019: Dividend per share 1.60 USD
  5. Fiscal year 2020: Dividend per share 1.66 USD
  6. Fiscal year 2021: Dividend per share 1.76 USD
  7. Fiscal year 2022: Dividend per share 1.84 USD
  8. Fiscal year 2023: Dividend per share 1.94 USD
  9. Fiscal year 2024: Dividend per share 2.04 USD
  10. Fiscal year 2025: Dividend per share 2.20 USD

Payout ratios

The payout ratio rose in 4 years from 23.8% to 27.6%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 21.5% · Payout ratio (free cash flow) 10.6%
  2. Fiscal year 2017: Payout ratio (earnings) 89.0% · Payout ratio (free cash flow) 30.9%
  3. Fiscal year 2018: Payout ratio (earnings) 20.2% · Payout ratio (free cash flow) 31.0%
  4. Fiscal year 2019: Payout ratio (earnings) 39.6% · Payout ratio (free cash flow) 16.7%
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) 18.7%
  6. Fiscal year 2021: Payout ratio (earnings) 23.8% · Payout ratio (free cash flow) 16.5%
  7. Fiscal year 2022: Payout ratio (earnings) 22.9% · Payout ratio (free cash flow) 17.7%
  8. Fiscal year 2023: Payout ratio (earnings) 22.7% · Payout ratio (free cash flow) 11.5%
  9. Fiscal year 2024: Payout ratio (earnings) 27.1% · Payout ratio (free cash flow) 13.9%
  10. Fiscal year 2025: Payout ratio (earnings) 27.6% · Payout ratio (free cash flow) 13.6%

What goes back to shareholders

Over 5 years, 5.7B USD went back to shareholders, 65% of it through share repurchases. That is 40% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 288.5M USD · Share repurchases 2.3B USD · New shares issued (including employee plans) not available · Free cash flow 2.7B USD
  2. Fiscal year 2017: Dividends paid 320.3M USD · Share repurchases 329.9M USD · New shares issued (including employee plans) not available · Free cash flow 1.0B USD
  3. Fiscal year 2018: Dividends paid 333.0M USD · Share repurchases 639.2M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 1.1B USD
  4. Fiscal year 2019: Dividends paid 339.0M USD · Share repurchases 674.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 2.0B USD
  5. Fiscal year 2020: Dividends paid 343.6M USD · Share repurchases 420.4M USD · New shares issued (including employee plans) 66.4M USD · Free cash flow 1.8B USD
  6. Fiscal year 2021: Dividends paid 366.6M USD · Share repurchases 82.2M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 2.2B USD
  7. Fiscal year 2022: Dividends paid 391.7M USD · Share repurchases 483.7M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 2.2B USD
  8. Fiscal year 2023: Dividends paid 398.8M USD · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow 3.5B USD
  9. Fiscal year 2024: Dividends paid 416.2M USD · Share repurchases 1.5B USD · New shares issued (including employee plans) not available · Free cash flow 3.0B USD
  10. Fiscal year 2025: Dividends paid 437.1M USD · Share repurchases 435.5M USD · New shares issued (including employee plans) not available · Free cash flow 3.2B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Cencora next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison COR, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health 402.1B USD +8.4%–1.2%0.4%2.4%29.7%1.9%7/9
COR Cencora this stock 321.3B USD +11.1%3.6%0.8%0.5%–2.0%1.0%7/9
CI Cigna 274.9B USD +11.4%–3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
Median of the sector 27 symbols 44.6B USD +9.4%67.2%17.8%13.2%14.3%38.4%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector COR next to CI – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+11.1% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 11.1% per year on average – at least as fast as the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

0.5% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 0.48 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was −1.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

3.84 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 3.84 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

28% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.28 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
321.3B USD
Revenue vs. prior year
+9.3%
Net income (FY)
1.6B USD
Net income vs. prior year
+3.0%
EPS (FY)
7.96 USD
Superinvestors holding
3 of 26
Fiscal year to Sep 30, 2025 · 10-K filed Nov 25, 2025 · Balance sheet Jun 30, 2026 (filed Aug 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Sep 30, 2025 321.3B1.6B 0.5% 7.96 2.20 28%
2024Sep 30, 2024 294.0B1.5B 0.5% 7.53 2.04 27%
2023Sep 30, 2023 262.2B1.7B 0.7% 8.53 1.94 23%
2022Sep 30, 2022 238.6B1.7B 0.7% 8.04 1.84 23%
2021Sep 30, 2021 214.0B1.5B 0.7% 7.39 1.76 24%
2020Sep 30, 2020 189.9B−3.4B −1.8% −16.65 1.66 –
2019Sep 30, 2019 179.6B855.4M 0.5% 4.04 1.60 40%
2018Sep 30, 2018 167.9B1.7B 1.0% 7.53 1.52 20%
2017Sep 30, 2017 153.1B364.5M 0.2% 1.64 1.46 89%
2016Sep 30, 2016 146.8B1.4B 1.0% 6.32 1.36 22%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 84.8B763.5M 0.9% 3.94 0.60 15%
Q1/26Mar 31, 2026 78.4B1.6B 2.1% 8.40 0.60 7%
Q4/25Dec 31, 2025 85.9B559.6M 0.7% 2.87 0.60 21%
Q3/25*Sep 30, 2025 83.7B−339.7M −0.4% – 0.55 –
Q2/25Jun 30, 2025 80.7B687.4M 0.9% 3.52 0.55 16%
Q1/25Mar 31, 2025 75.5B717.9M 1.0% 3.68 0.55 15%
Q4/24Dec 31, 2024 81.5B488.6M 0.6% 2.50 0.55 22%
Q3/24*Sep 30, 2024 79.1B3.4M 0.0% – 0.51 –
Q2/24Jun 30, 2024 74.2B483.5M 0.7% 2.42 0.51 21%
Q1/24Mar 31, 2024 68.4B420.8M 0.6% 2.09 0.51 24%
Q4/23Dec 31, 2023 72.3B601.5M 0.8% 2.98 0.51 17%
Q3/23*Sep 30, 2023 68.9B350.6M 0.5% – 0.49 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $5.0M3 people −$5.0M
6 months $2.3M2 people $5.0M3 people −$2.7M
12 months $2.3M2 people $13.5M5 people −$11.2M

Latest transactions

  • Nov 2, 2026 Krikorian Lazarus Officer Open-market sale · 10b5-1 plan 986 shares · $326.3K · SEC
  • Oct 1, 2026 Krikorian Lazarus Officer Open-market sale · 10b5-1 plan 986 shares · $298.9K · SEC
  • Sep 16, 2026 Greenberg Lon R Director Open-market sale 1,280 shares · $411.3K · SEC
  • Sep 1, 2026 Krikorian Lazarus Officer Open-market sale · 10b5-1 plan 985 shares · $321.1K · SEC
  • Aug 24, 2026 Campbell Elizabeth S Officer Open-market sale 11,300 shares · $3.7M · SEC
  • Jun 22, 2026 Tyler Lauren M Director Open-market purchase 550 shares · $148.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Cencora?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Cencora, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Steve Cohen Point72 Asset Management 0.3% +9.0% increased Q3 2026
Renaissance Technologies < 0.1% +874.5% increased Q3 2026
Bridgewater Associates < 0.1% +48.0% increased Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on COR yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: COR

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close